These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11174760)

  • 41. High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma.
    Vora SA; Daly BD; Blaszkowsky L; McGrath JJ; Bankoff M; Supran S; Dipetrillo TA
    Cancer; 2000 Nov; 89(9):1946-52. PubMed ID: 11064351
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer.
    Brade A; Bezjak A; MacRae R; Laurie S; Sun A; Cho J; Leighl N; Pearson S; Southwood B; Wang L; McGill S; Iscoe N; Shepherd FA
    Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1395-401. PubMed ID: 20605367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of radiologic stage III substage on nonsurgical therapy of non-small cell lung cancer.
    Kreisman H; Lisbona A; Olson L; Propert KJ; Modeas C; Dillman RO; Seagren SL; Green MR
    Cancer; 1993 Sep; 72(5):1588-96. PubMed ID: 8394201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC).
    Ishikura S; Ohe Y; Nihei K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Nishiwaki Y; Ogino T
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1117-22. PubMed ID: 15752891
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant chemotherapy in non-small cell lung cancer (NSCLC).
    Felip E; Cedrés S; Peralta S; Prat A
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix143-6. PubMed ID: 17631567
    [No Abstract]   [Full Text] [Related]  

  • 47. [Role of chemotherapy in non-small cell lung carcinoma].
    Giaccone G; Dingemans AM
    Ned Tijdschr Geneeskd; 1996 May; 140(21):1111-4. PubMed ID: 8692336
    [No Abstract]   [Full Text] [Related]  

  • 48. [Place of radiotherapy in treatment of non small cell lung cancer].
    Chmielewska E; Jodkiewicz Z
    Pneumonol Alergol Pol; 2002; 70(1-2):110-6. PubMed ID: 12148171
    [No Abstract]   [Full Text] [Related]  

  • 49. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
    Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
    Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
    Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NSCLC: primary tumor size--radiation dose-related accelerated, twice daily radiotherapy by target splitting, preceded by 2 cycles of chemotherapy--first results of a prospective study.
    Wurstbauer K; Deutschmann H; Kopp P; Kranzinger M; Merz F; Nairz O; Studnicka M; Sedlmayer F
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():38-40. PubMed ID: 18167008
    [No Abstract]   [Full Text] [Related]  

  • 52. Combined modality therapy of non-small cell lung cancers.
    Juretic A; Sobat H; Samija M
    Ann Oncol; 1999; 10 Suppl 6():93-8. PubMed ID: 10676559
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-surgical therapy for patients with advanced non-small cell lung cancer.
    Clarke SJ; Boyer MJ
    Respirology; 1998 Sep; 3(3):175-82. PubMed ID: 9767616
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study.
    Bonner JA; McGinnis WL; Stella PJ; Marschke RF; Sloan JA; Shaw EG; Mailliard JA; Creagan ET; Ahuja RK; Johnson PA
    Cancer; 1998 Mar; 82(6):1037-48. PubMed ID: 9506347
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer.
    Blanke C; DeVore R; Shyr Y; Epstein B; Murray M; Hande K; Stewart S; Johnson D
    Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):111-6. PubMed ID: 9054884
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Radiation and chemotherapy for patients with stage III non-small cell lung cancer.
    Green MR; Rocha Lima CM; Sherman CA
    Semin Radiat Oncol; 2000 Oct; 10(4):289-95. PubMed ID: 11040329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer.
    Zhang Q; Cai XW; Zhu ZF; Yu W; Liu Q; Feng W; Xue MC; Fu XL
    Anticancer Drugs; 2015 Apr; 26(4):456-63. PubMed ID: 25646743
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Multimodal treatment of non small cell lung cancer].
    Stoelben E; Digel W; Henke M; Passlick B
    Zentralbl Chir; 2006 Apr; 131(2):110-4. PubMed ID: 16612776
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-small cell lung cancer, nonsurgical, aggressive therapy. American College of Radiology. ACR Appropriateness Criteria.
    Komaki R; Sause WT; Byhardt RW; Curran WJ; Fuller D; Graham MV; Ko B; Weisenburger TH; Kaiser LR; Leibel SA; Choi NC
    Radiology; 2000 Jun; 215 Suppl():1319-30. PubMed ID: 11037549
    [No Abstract]   [Full Text] [Related]  

  • 60. A phase II trial of radiochemotherapy with daily carboplatin, after induction chemotherapy (carboplatin and etoposide), in locally advanced nonsmall-cell lung cancer: final analysis.
    Bardet E; Rivière A; Charloux A; Spaeth D; Ducoloné A; Le Groumellec A; Pellae-Cosset B; Henry-Amar M; Douillard JY
    Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):163-8. PubMed ID: 9212019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.